VIVUS to Present at the Credit Suisse 2011 Healthcare Conference

MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Credit Suisse 2011 Healthcare Conference.

The VIVUS presentation will take place at the Arizona Biltmore Hotel in Phoenix, AZ on Thursday, November 10, 2011 at 9:30 a.m. MST.  A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.       

About VIVUS

VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, Qnexa®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial Qnexa NDA on October 28, 2010. Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction, with an FDA action date of April 29, 2012. For more information about the company, please visit www.vivus.com.

 

CONTACT:  

 

 

 

 

 

VIVUS, Inc.   

 Investor Relations:  

The Trout Group       

 

 

 

Timothy E. Morris                     

 

Brian Korb


Chief Financial Officer                  

 

[email protected]

 

 

 

650-934-5200                             

 

646-378-2923                                     

 

                                               

SOURCE VIVUS, Inc.

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.